KR100717661B1 - 신규 제형 - Google Patents

신규 제형 Download PDF

Info

Publication number
KR100717661B1
KR100717661B1 KR1020017016442A KR20017016442A KR100717661B1 KR 100717661 B1 KR100717661 B1 KR 100717661B1 KR 1020017016442 A KR1020017016442 A KR 1020017016442A KR 20017016442 A KR20017016442 A KR 20017016442A KR 100717661 B1 KR100717661 B1 KR 100717661B1
Authority
KR
South Korea
Prior art keywords
core material
formulation
omeprazole
active ingredient
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020017016442A
Other languages
English (en)
Korean (ko)
Other versions
KR20020012002A (ko
Inventor
페르 요한 룬드베르그
브리타 쇼블롬
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20020012002A publication Critical patent/KR20020012002A/ko
Application granted granted Critical
Publication of KR100717661B1 publication Critical patent/KR100717661B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
KR1020017016442A 1999-06-22 2000-06-20 신규 제형 Expired - Fee Related KR100717661B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9902386A SE9902386D0 (sv) 1999-06-22 1999-06-22 New formulation
SE9902386-3 1999-06-22

Publications (2)

Publication Number Publication Date
KR20020012002A KR20020012002A (ko) 2002-02-09
KR100717661B1 true KR100717661B1 (ko) 2007-05-14

Family

ID=20416209

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017016442A Expired - Fee Related KR100717661B1 (ko) 1999-06-22 2000-06-20 신규 제형

Country Status (29)

Country Link
EP (1) EP1191926B1 (enExample)
JP (1) JP2003502359A (enExample)
KR (1) KR100717661B1 (enExample)
CN (1) CN1243547C (enExample)
AT (1) ATE291901T1 (enExample)
AU (1) AU778158B2 (enExample)
BR (1) BR0011894A (enExample)
CA (1) CA2376226C (enExample)
CZ (1) CZ20014579A3 (enExample)
DE (1) DE60019116T2 (enExample)
DK (1) DK1191926T3 (enExample)
EE (1) EE200100693A (enExample)
ES (1) ES2235912T3 (enExample)
HK (1) HK1044480B (enExample)
HU (1) HUP0201489A3 (enExample)
IL (2) IL146818A0 (enExample)
IS (1) IS6209A (enExample)
MX (1) MXPA01012636A (enExample)
NO (1) NO20016346L (enExample)
NZ (1) NZ516186A (enExample)
PL (1) PL352873A1 (enExample)
PT (1) PT1191926E (enExample)
RU (1) RU2240110C2 (enExample)
SE (1) SE9902386D0 (enExample)
SK (1) SK285326B6 (enExample)
TR (1) TR200103693T2 (enExample)
UA (1) UA73302C2 (enExample)
WO (1) WO2000078293A1 (enExample)
ZA (1) ZA200109803B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
PT1492511E (pt) 2002-04-09 2009-04-09 Flamel Tech Sa Formulação farmacêutica oral na forma de suspensão aquosa de microcápsulas para libertação modificada de princípio(s) activo(s)
SI21402A (sl) 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
CA2517289A1 (en) * 2003-02-28 2004-09-10 Ranbaxy Laboratories Limited Stable pharmaceutical composition of rabeprazole and processes for their preparation
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1696889A1 (en) * 2003-08-28 2006-09-06 Ranbaxy Laboratories, Ltd. Pharmaceutical compositions of benzimidazole and processes for their preparation
MXPA06002443A (es) * 2003-09-03 2006-08-31 Agi Therapeutics Ltd Formulaciones inhibidoras de la bomba de protones y metodos para preparar y utilizar tales formulaciones.
US7699964B2 (en) 2004-02-09 2010-04-20 Abbott Diabetes Care Inc. Membrane suitable for use in an analyte sensor, analyte sensor, and associated method
US8165651B2 (en) 2004-02-09 2012-04-24 Abbott Diabetes Care Inc. Analyte sensor, and associated system and method employing a catalytic agent
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AU2005275594A1 (en) * 2004-08-23 2006-03-02 Synergy Pharmaceuticals Pte Ltd Gastric therapies and compositions therefor
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
FR2885526B1 (fr) * 2005-05-13 2007-07-27 Flamel Technologies Sa Medicament oral a base d'inhibiteur de pompe a protons
ZA200711123B (en) 2005-06-27 2009-08-26 Biovail Lab Int Srl Modified-release formulations of a bupropion salt
SG184754A1 (en) * 2005-12-28 2012-10-30 Takeda Pharmaceutical Controlled release solid preparation
US7885698B2 (en) 2006-02-28 2011-02-08 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
PL2046334T3 (pl) 2006-07-25 2015-02-27 Vecta Ltd Kompozycje i sposoby hamowania wydzielania kwasów żołądkowych z wykorzystaniem pochodnych małych kwasów dikarboksylowych w połączeniu z PPI
WO2008044236A2 (en) * 2006-10-10 2008-04-17 Dexcel Pharma Technologies Ltd. Improved release of statins in the intestine
EA201100313A1 (ru) 2008-09-09 2011-10-31 Астразенека Аб Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом
CA2764963C (en) 2009-06-25 2016-11-01 Astrazeneca Ab Method for treating a patient at risk for developing an nsaid-associated ulcer
KR102158948B1 (ko) 2011-05-13 2020-09-24 이비 아이피 하이브리탭스 비.브이. 약물 전달 시스템
EP2586429A1 (en) * 2011-10-26 2013-05-01 Freund Pharmatec Ltd. Multi-unit drug delivery device for pulsatile or sustained release
US9539214B2 (en) 2011-12-28 2017-01-10 Pozen Inc. Compositions and methods for delivery of omeprazole plus acetylsalicylic acid
WO2013122554A1 (en) 2012-02-14 2013-08-22 Mahmut Bilgic Pellet formulations comprising esomeprazole
CN103127026B (zh) * 2013-02-05 2017-02-15 悦康药业集团有限公司 一种奥美拉唑肠溶胶囊及其制备方法
EP3089666B1 (en) 2013-12-31 2020-08-19 Abbott Diabetes Care Inc. Self-powered analyte sensor and devices using the same
WO2016174664A1 (en) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
RU2614730C1 (ru) * 2016-02-05 2017-03-28 Игорь Юрьевич Чичерин Антибактериальное средство и способ лечения кишечного иерсиниоза, или псевдотуберкулеза, или эшерихиоза
WO2017145146A1 (en) * 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
JP6462625B2 (ja) * 2016-04-06 2019-01-30 ニプロ株式会社 カルシウムブロッカーを含有する錠剤
JP6426115B2 (ja) * 2016-04-06 2018-11-21 ニプロ株式会社 カルシウムブロッカーを含有する固形医薬組成物
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN109125282B (zh) * 2018-09-05 2020-07-14 珠海润都制药股份有限公司 一种奥美拉唑肠溶胶囊及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0237200A2 (en) * 1986-02-13 1987-09-16 Takeda Chemical Industries, Ltd. Use of basic inorganic salts of magnesium or calcium for the stabilisation of benzimidazole derivatives
WO1997025979A1 (en) * 1996-01-18 1997-07-24 Perio Products Ltd. Gastrointestinal drug delivery system

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
DE69729950T2 (de) * 1996-11-06 2005-07-28 Wockhardt Europe Ltd. Arzneimittel-Zuführsystem mit verzögerter Freisetzung für säurelabile Arzneistoffe
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
ES2216351T3 (es) * 1997-12-08 2004-10-16 Altana Pharma Ag Nueva forma de supositorio que comprende un compuesto activo labil o acidos.
ATE321538T1 (de) * 1998-08-12 2006-04-15 Altana Pharma Ag Orale darreichungsform für pyridin-2- ylmethylsulfinyl-1h-benzimidazole

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0237200A2 (en) * 1986-02-13 1987-09-16 Takeda Chemical Industries, Ltd. Use of basic inorganic salts of magnesium or calcium for the stabilisation of benzimidazole derivatives
WO1997025979A1 (en) * 1996-01-18 1997-07-24 Perio Products Ltd. Gastrointestinal drug delivery system

Also Published As

Publication number Publication date
PL352873A1 (en) 2003-09-08
CA2376226A1 (en) 2000-12-28
SE9902386D0 (sv) 1999-06-22
CN1356893A (zh) 2002-07-03
CZ20014579A3 (cs) 2002-05-15
CA2376226C (en) 2009-10-20
JP2003502359A (ja) 2003-01-21
PT1191926E (pt) 2005-07-29
IL146818A0 (en) 2002-07-25
HK1044480A1 (en) 2002-10-25
AU6034400A (en) 2001-01-09
EP1191926B1 (en) 2005-03-30
KR20020012002A (ko) 2002-02-09
NO20016346L (no) 2002-02-18
RU2240110C2 (ru) 2004-11-20
IL146818A (en) 2007-10-31
AU778158B2 (en) 2004-11-18
HUP0201489A2 (hu) 2002-11-28
SK18252001A3 (sk) 2002-09-10
DE60019116T2 (de) 2006-02-09
MXPA01012636A (es) 2002-06-21
WO2000078293A1 (en) 2000-12-28
EE200100693A (et) 2003-02-17
HK1044480B (en) 2005-08-26
DK1191926T3 (da) 2005-06-13
NO20016346D0 (no) 2001-12-21
NZ516186A (en) 2003-11-28
TR200103693T2 (tr) 2002-05-21
EP1191926A1 (en) 2002-04-03
CN1243547C (zh) 2006-03-01
HUP0201489A3 (en) 2004-05-28
UA73302C2 (en) 2005-07-15
ATE291901T1 (de) 2005-04-15
ES2235912T3 (es) 2005-07-16
BR0011894A (pt) 2002-04-02
DE60019116D1 (de) 2005-05-04
SK285326B6 (sk) 2006-11-03
ZA200109803B (en) 2003-02-28
IS6209A (is) 2001-12-21

Similar Documents

Publication Publication Date Title
KR100717661B1 (ko) 신규 제형
CA2290531C (en) Pharmaceutical formulation of omeprazole
KR100616027B1 (ko) 경구용 제약학적 펄스 방출형 투여 제형
AU774278B2 (en) Pharmaceutical formulation comprising omeprazole
JPH09502739A (ja) 複数単位の錠剤化された剤形▲ｉ▼
AU5791900A (en) Solid oral pharmaceutical formulation of modified release that contains an acid labile benzimidazole compound
MXPA00005895A (en) Oral pharmaceutical pulsed release dosage form
HK1025744B (en) Pharmaceutical formulation of omeprazole

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20100508

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20100508

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000